Intensity Therapeutics Inc INTS

NAS: INTS | ISIN: US45828J1034   8/07/2025
0,290 USD (+2,40%)
(+2,40%)   8/07/2025

13 mei 2025 · Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update · Persbericht

6 mei 2025 · Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France · Persbericht

25 april 2025 · Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering · Persbericht

13 maart 2025 · Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update · Persbericht

4 september 2024 · Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

8 augustus 2024 · Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

9 juli 2024 · Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma · Persbericht

15 mei 2024 · Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors · Persbericht

10 mei 2024 · Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate · Persbericht

9 mei 2024 · Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

2 april 2024 · Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 · Persbericht

14 maart 2024 · Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update · Persbericht

14 maart 2024 · Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 · Persbericht

21 februari 2024 · Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference · Persbericht

3 januari 2024 · Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program · Persbericht

12 december 2023 · Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer · Persbericht

8 december 2023 · Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS · Persbericht

1 december 2023 · Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium · Persbericht

2 november 2023 · Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023 · Persbericht

7 september 2023 · Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma · Persbericht

Mijn selecties